Description
Lamivudine & Zidovudine Tablets (150 mg / 300 mg)
Healthy Inc is a premier global provider of high-potency antiretroviral therapies. We provide premium Lamivudine and Zidovudine Tablets, manufactured in WHO–GMP certified specialized HIV/AIDS production blocks. As a cornerstone dual-NRTI combination for HIV-1 management, this product is a vital export for infectious disease clinics, sexual health centers, and Ministry of Health (MOH) tenders in Sub-Saharan Africa, Southeast Asia, and the CIS region.
Product Overview
This fixed-dose combination (FDC) combines two nucleoside reverse transcriptase inhibitors (NRTIs). By providing synergistic inhibition of the HIV reverse transcriptase enzyme, it effectively halts the replication of the virus, reduces viral load, and helps restore the patient’s immune function.
The “Double Barrier” Antiretroviral Specialist:
- Synergistic Mechanism of Action: Both Lamivudine (3TC) and Zidovudine (AZT) are intracellularly phosphorylated to their active triphosphate metabolites. These molecules compete with natural deoxynucleotides for incorporation into viral DNA. Once incorporated, they act as “chain terminators,” preventing the formation of the proviral DNA strand.
- Foundational Therapy: This combination is a preferred backbone for highly active antiretroviral therapy (HAART), typically used in conjunction with a third agent such as a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI).
- PEP Protocols: Beyond chronic management, this combination is the global standard for Post-Exposure Prophylaxis (PEP) following occupational or non-occupational exposure to HIV.
Technical & Manufacturing Specifications
Formulated for absolute dose precision and synchronized intracellular activation.
| Technical Metric | Specification Standard |
|---|---|
| Active Ingredients | Lamivudine + Zidovudine BP / USP / IP |
| Dosage Form | Film-Coated Tablets |
| Standard Strength | 150 mg Lamivudine + 300 mg Zidovudine |
| HS Code | 3004.90.99 (Antiretroviral Medicaments) / 2933.59.90 |
| Packaging | HDPE Bottles with Desiccant or Alu-Alu Blisters |
Manufacturing Authority
Marketed and Distributed by Healthy Inc from ISO 9001:2015 certified units.
- HAPI Containment: Manufactured in high-containment facilities to prevent cross-contamination, ensuring the highest safety standards for immuno-compromised patients.
- Optimized Bioavailability: Our formulation ensures that both APIs are released simultaneously, facilitating consistent plasma levels and preventing the development of drug resistance.
- Stability Validation: Validated for Climatic Zone IVb. Our tablets are engineered to withstand high humidity and temperature, maintaining potency for 36 months in tropical and sub-tropical export markets.
Therapeutic Indications & Clinical Symptoms
- HIV-1 Infection: Treatment of HIV-infected adults and children weighing over 30 kg.
- Post-Exposure Prophylaxis (PEP): Emergency prevention of infection following potential exposure to HIV.
- PMTCT: Part of multi-drug regimens to prevent mother-to-child transmission during pregnancy and labor.
Dosage & Administration
- Adults and Adolescents: One tablet (150/300 mg) twice daily.
- Renal Adjustment: Not recommended for patients with a Creatinine Clearance < 50 mL/min; individual components should be used instead.
- Safety Note: Monitor for Hematologic Toxicity (anemia and neutropenia) and Lactic Acidosis. Patients should be screened for Hepatitis B (HBV) co-infection before starting therapy.
Global Export & Contract Manufacturing Services
Healthy Inc is a verified Antiretroviral Exporter in Mumbai, catering to HIV Specialty Centers and International Relief Tenders. We offer Third Party Manufacturing for Lamivudine & Zidovudine with full CTD Dossier and COPP support. Our logistics network ensures secure transit to Nigeria, Kenya, Vietnam, and South Africa, providing WHO-GMP quality at competitive B2B prices.
Commercial Inquiries
WhatsApp/Call: +91 7710003340
Email: info@healthyinc.co.in
